Healthcare resource utilization and costs in patients with newly diagnosed acute myeloid leukemia

被引:35
作者
Hagiwara, May [1 ]
Sharma, Arati [1 ]
Chung, Karen C. [2 ]
Delea, Thomas E. [1 ]
机构
[1] PAI, 4 Davis Court, Brookline, MA 02445 USA
[2] Jazz Pharmaceut Inc, Palo Alto, CA USA
关键词
AML; healthcare resource utilization; costs; newly diagnosed; TREATMENT PATTERNS; OUTCOMES;
D O I
10.1080/13696998.2018.1513847
中图分类号
F [经济];
学科分类号
02 ;
摘要
Aim: Acute myeloid leukemia (AML) is associated with high disease burden. This analysis estimated HRU and costs among newly diagnosed AML patients in a US commercially insured population. Materials and methods: This was a retrospective observational study using the IMS Health PharMetrics Plus and Hospital Charge Detail Master databases. Patients included adults who were newly diagnosed with AML between January 2007 and June 2016 ("study period"). Patients with <12 months of continuous enrollment prior to the index date were excluded, as were those whose first diagnosis was AML in remission/relapse, those diagnosed with acute promyelocytic leukemia, those on Medicare supplemental insurance, or those with a diagnosis of AML in remission/relapse without evidence of treatment during the study period. Patients were stratified by receipt of AML treatment (chemotherapy/hematopoietic cell transplantation [HCT]), and their follow-up was partitioned into initial, remission, and relapsed health states. Mean HRU and costs were tallied by treatment and, for treated patients, by health state and time since entry into health state (<= 6 vs >6 months). Results: A total of 9,455 patients met study criteria, including 6,415 (68%) treated and 3,040 (32%) untreated patients, with mean follow-up of 18.3 and 16.4 months, respectively. Mean age was 55 years in treated patients and 60 years in untreated patients. Mean total costs per patient were $386,077 in treated patients and $79,382 in untreated patients. For treated patients, 60% of total costs ($231,867 per patient) were incurred during the initial health state, representing time without remission/relapse. Mean monthly total healthcare costs were $21,055 and $4,854 among treated and untreated patients, respectively. Limitations and conclusions: HRU and costs of managing AML patients are substantial. In treated patients, the majority of costs were incurred during the initial treatment period, without claims indicating remission/relapse.
引用
收藏
页码:1119 / 1130
页数:12
相关论文
共 14 条
[1]  
[Anonymous], 2017, Cancer facts & fi gures 2017-special section: rare cancers in adults
[2]  
Bell JA, 2017, 59 ANN AM SOC HEM M
[3]   Acute myeloid leukemia:: Epidemiology and etiology [J].
Deschler, Barbara ;
Luebbert, Michael .
CANCER, 2006, 107 (09) :2099-2107
[4]  
IMS Health IMS LifeLink, 2013, IMS LIFELINK PHARMET
[5]   Acute myeloid leukemia: a retrospective claims analysis of resource utilization and expenditures for newly diagnosed patients from first-line induction to remission and relapse [J].
Irish, William ;
Ryan, Michael ;
Gache, Larry ;
Gunnarsson, Candace ;
Bell, Timothy ;
Shapiro, Mark .
CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (03) :519-527
[6]  
Karen Seiter M, 2016, ACUTE MYELOID LEUKEM
[7]   Outcomes and charges of elderly patients with acute myeloid leukemia [J].
Katz, Laura M. ;
Howell, Jamie B. ;
Doyle, John J. ;
Stern, Lee S. ;
Rosenblatt, Lisa C. ;
Piech, Catherine Tak ;
Zilberberg, Marya D. .
AMERICAN JOURNAL OF HEMATOLOGY, 2006, 81 (11) :850-857
[8]  
Medeiros BC, 2017, 59 ANN AM SOC HEM M
[9]   Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States [J].
Medeiros, Bruno C. ;
Satram-Hoang, Sacha ;
Hurst, Deborah ;
Hoang, Khang Q. ;
Momin, Faiyaz ;
Reyes, Carolina .
ANNALS OF HEMATOLOGY, 2015, 94 (07) :1127-1138
[10]   Medicare fee-for-service enrollees with primary acute myeloid leukemia: An analysis of treatment patterns, survival, and healthcare resource utilization and costs [J].
Meyers J. ;
Yu Y. ;
Kaye J.A. ;
Davis K.L. .
Applied Health Economics and Health Policy, 2013, 11 (3) :275-286